Literature DB >> 6225746

Ulceration is correlated with degradation of fibrin and fibronectin at the corneal surface.

M Berman, E Manseau, M Law, D Aiken.   

Abstract

Although ulceration of the corneal stroma after alkali burns is known to be correlated with persistent epithelial defects, the relationship between a defect and the mediators thought to contribute to stromal destruction (plasminogen activator, plasmin, collagenase) has not been understood. This report demonstrates that fibrin and fibronectin appear on the stromal surface after an alkali burn, and that those substratum, matrix components disappear in correlation with the appearance of plasminogen activator on the stromal surface, re-surfacing by the epithelium and a persistent epithelial defect. The facts that epithelium releases plasminogen activator and that plasmin, generated from plasminogen by an activator, can degrade both fibrin and fibronectin, as well as the laminin component of the subepithelial basement membrane, would suggest that the plasminogen activator-plasmin system effect degradation of those macromolecules, thus initiating the events that lead to eventual, frank stromal ulceration. It is hypothesized that stromal ulceration is initiated by the chronic secretion from an epithelium with a persistent defect of a protease (plasminogen activator) involved in wound healing.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225746

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Expression of tenascin and fibronectin in the rabbit cornea after excimer laser surgery.

Authors:  G B van Setten; J W Koch; K Tervo; G K Lang; T Tervo; G O Naumann; J Kolkmeier; I Virtanen; A Tarkkanen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

2.  αVβ6 integrin promotes corneal wound healing.

Authors:  José Tomás Blanco-Mezquita; Audrey E K Hutcheon; Mary Ann Stepp; James D Zieske
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

3.  Pharmacokinetics of polyvalent proteinase inhibitor (aprotinin) in eye tissues.

Authors:  N B Chesnokova; T P Kuznetsova; N E Sosulina
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

4.  Expression of fibronectin receptor (integrin) in the uterus of rats in relation to the estrous cycle.

Authors:  T Nishida; J Murakami; T Otori
Journal:  Histochemistry       Date:  1991

5.  Epidermal growth factor is a constant component of normal human tear fluid.

Authors:  G B van Setten; L Viinikka; T Tervo; K Pesonen; A Tarkkanen; J Perheentupa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

6.  Histochemical study of alkali-burned rabbit anterior eye segment in which severe lesions were prevented by aprotinin treatment.

Authors:  J Cejková; Z Lojda; E M Salonen; A Vaheri
Journal:  Histochemistry       Date:  1989

7.  The histochemical pattern of mechanically or chemically injured rabbit cornea after aprotinin treatment: relationships with the plasmin concentration of the tear fluid.

Authors:  J Cejková; Z Lojda; S Dropcová; D Kadlecová
Journal:  Histochem J       Date:  1993-06

8.  Histochemical changes in the rabbit cornea and plasmin activity in the tear fluid during contact lens wear. Favourable influence of protease inhibitors (aprotinin, PC5, elastatinal).

Authors:  J Cejková; Z Lojda; J Vacík; G A Digenis; S Dropcova
Journal:  Histochemistry       Date:  1992

9.  Contact lens wear is associated with the appearance of plasmin in the tear fluid--preliminary results.

Authors:  T Tervo; G B van Setten; R Andersson; E M Salonen; A Vaheri; I Immonen; A Tarkkanen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

10.  Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.

Authors:  Francesco Semeraro; Eliana Forbice; Osvaldo Braga; Alessandro Bova; Attilio Di Salvatore; Claudio Azzolini
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.